The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis

References

• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol. 2007;157(1):68–73.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450–456.
   PubMed Web of Science ®Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol. 2019;58(6):649–658.
   PubMed Web of Science ®Google Scholar
• [ cited 2019 July]. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
   Google Scholar
• [ cited 2019 July]. https://www.ema.europa.eu/en/medicines/human/EPAR/taltz
   Google Scholar
• [ cited 2019 July]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-psoriasis-drug
   Google Scholar
• Thomas LW, Lee EB, Wu JJ. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. J Dermatolog Treat. 2019;30(2):110–116.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Massaro A, et al. Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. Clin Cosmet Investig Dermatol. 2019;12:311–321.
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Senra L, Boehncke W-H. Senra L and Boehncke W. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Papp K, Kircik L. Secukinumab: review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR. J Clin Aesthet Dermatol. 2016;9(6 Suppl 1):S7–S12.
   PubMedGoogle Scholar
• Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686–1692.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s Disease. Am J Gastroenterol. 2016;111(11):1599–1607.
   PubMed Web of Science ®Google Scholar
• Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016;8(3):536–550.
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatological Treat. 2017;29(1):13–18.
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98e4.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJB, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase three trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   PubMed Web of Science ®Google Scholar
• Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135–144.
   PubMed Web of Science ®Google Scholar
• von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 Weeks. J Invest Dermatol. 2019;139(5):1054–1062.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727–735.
   PubMed Web of Science ®Google Scholar
• Papini M, Natalini Y. Candida infections in psoriatic patients on anti-IL17 therapy: a case series. J Dermatolog Treat. 2018;29(sup2):3–4.
   PubMed Web of Science ®Google Scholar
• Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855–861.
   PubMed Web of Science ®Google Scholar
• Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205–1207.
   PubMed Web of Science ®Google Scholar
• Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–440.e17.
   PubMed Web of Science ®Google Scholar
• Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33(2):33–339.
   PubMed Web of Science ®Google Scholar
• Rusta-Sallehy S, Gooderham M, Papp K. Brodalumab: a review of safety. Skin Therapy Lett. 2018;23(2):1–3.
   PubMedGoogle Scholar
• Roostaeyan O, Kivelevitch D, Menter A. A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis. Immunotherapy. 2017;9(12):963–978.
   PubMed Web of Science ®Google Scholar
• Puig L, Lebwohl M, Bachelez, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2019.  doi: 10.1016/j.jaad.2019.05.095. Epub ahead of print.
   Web of Science ®Google Scholar
• Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 2014;25(4):415–421.
   PubMed Web of Science ®Google Scholar
• Jeon C, Sekhon S, Yan D, et al. Monoclonal antibodies inhibiting IL-12, −23, and −17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;13(10):2247–2259.
   PubMed Web of Science ®Google Scholar
• Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29(7):615–624.
   PubMed Web of Science ®Google Scholar
• [ cited 2019 July]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761044Orig1s000TOC.cfm
   Google Scholar
• D’Adamio S, Silvaggio D, Massaro A, et al. Pharmacotherapeutic management of psoriasis in adolescents and children. Expert Opin Pharmacother. 2019;4:1–9.
   Google Scholar
• [ cited 2019 July]. https://www.ema.europa.eu/en/medicines/human/EPAR/stelara
   Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019 Jan;80(1):43–53. . Epub 2018 Jul 11.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–592.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–252.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154–163.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaquetype psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166–174.
   PubMed Web of Science ®Google Scholar
• Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–1383.
   PubMed Web of Science ®Google Scholar
• Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatological Treat. 2018;29(6):569–578.
   PubMed Web of Science ®Google Scholar
• Lunder T, Zorko MS, Kolar NK, et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019;58(6):631–641.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Bianchi L, et al. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatolog Treat. 2019;30(1):40–44.
   PubMed Web of Science ®Google Scholar
• Watson N, Wu K, Farr P, et al. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. Br J Dermatol. 2019;180(1):195–196.
   PubMed Web of Science ®Google Scholar
• Megna M, Villani A, Balato N, et al. Letter to the editor submitted in response to “psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab”. J Dermatolog Treat. 2019;30(3):309.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264–272.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
   PubMed Web of Science ®Google Scholar
• Janssen Biotech Inc. Janssen announces U.S. FDA approval of TREMFYA(T) (guselkumab) for the treatment of moderate to severe plaque psoriasis [media release]. 13 July 2017. http://www.janssen.com. Last accessed on Jul 2019.
   Google Scholar
• European Medicines Agency. 2017. Available at: https://www.medicines.org.uk/emc/medicine/34321. Last accessed Jul 2019.
   Google Scholar
• FDA approves Ilumya for plaque psoriasis. National Psoriasis Foundation. March 22, 2018.
   Google Scholar
• [ cited 2019 July]. https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri
   Google Scholar
• AbbVie. AbbVie submits biologics license application to U.S. FDA for investigational treatment risankizumab for moderate to severe plaque psoriasis. April 25, 2018 press release. [cited 2019 July]. https://news.abbvie.com/news/abbvie-submits-biologics-license-application-to-us-fda-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis.htm
   Google Scholar
• European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis at [ cited 2019 July]. https://news.abbvie.com.press/news/-releases/european-commission-approves-skyrizi-risankizumab-for-treatment-moderate-to-severe-plaque-psoriasis.htm
   Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase 3 NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123.
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2019;33(9):1676–1684. Epub ahead of print.
   Google Scholar
• Galluzzo M, D’Adamio S, Campione E, et al. A safety evaluation of Guselkumab for the treatment of psoriasis. Expert Opin Drug Saf. 2018;17(7):741–751.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180(5):1039–1049.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615622.
   Web of Science ®Google Scholar
• Papp K, Thaçi D, Reich, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–939.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomised phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2019. doi: 10.1111/bjd.18232. Epub ahead of print.
   Web of Science ®Google Scholar
• Haugh IM, Preston AK, Kivelevitch DN, et al. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Dev Ther. 2018;12:3879–3883.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Gooderham M, et al. Risankizumab efficacy/safety in moderate-to-severe plaque psoriasis: 16-week results from immhance. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Bachelez H, Wu JJ et al. Long-term safety of risankizumab in patients with moderate to severe psoriasis: analysis of pooled clinical trial data. Poster from AAD Annual Meeting 2019, Washington DC.
   Google Scholar
• Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145–1152.
   PubMed Web of Science ®Google Scholar
• Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology. 2017;6(8):e152.
   PubMedGoogle Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509.
   PubMed Web of Science ®Google Scholar
• Zang M, Li Y, He H, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection. Biochim Biophys Acta Mol Basis Dis. 2018;1864(12):3759–3770.
   PubMed Web of Science ®Google Scholar
• [ cited 2019 July]. https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-bacterial-viral-and-fungal-infections
   Google Scholar
• Desai SB, Furst DE. Problems encountered during antitumor necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20(4):757–790.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Singh M. Anti-tumor necrosis factor-a therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol. 2016;99(6):391–397.
   Google Scholar
• Xie X, Li F, Chen JW, et al. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside. J Microbiol Immunol Infect. 2014;47(4):268–274.
   PubMedGoogle Scholar
• Keystone EC, Papp KA, Wobeser W. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol. 2011;38(7):1234e43.
   Web of Science ®Google Scholar
• Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299–311.
   PubMed Web of Science ®Google Scholar
• Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332:65–68.
   PubMed Web of Science ®Google Scholar
• Aguado JM, Manuel O. Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective. Clin Microbiol Infect. 2018 Jun; 24(Suppl 2):S1.
   PubMedGoogle Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687.
   PubMed Web of Science ®Google Scholar
• Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 2015;26(1):25–33.
   PubMed Web of Science ®Google Scholar
• Cao X, Leonard K, Collins LI, et al. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 2009;69:8700–8709.
   PubMed Web of Science ®Google Scholar
• Garcia K, Sun Z, Mattson E, et al. IL-12 is required for mTOR regulation of memory CTLs during viral infection. Genes Immun. 2014;15:413–423.
   PubMed Web of Science ®Google Scholar
• Haraguchi S, NK D, RP N, et al. Interleukin 12 deficiency associated with recurrent infections. Proc Natl Acad Sci U S A. 1998;95:13125–13129.
   PubMed Web of Science ®Google Scholar
• Kulig P, Musiol S, Freiberger SN, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466.
   PubMed Web of Science ®Google Scholar
• Zepeda-Morales AS, Del Toro-Arreola S, García-Benavides L, et al. Liver fibrosis in bile duct-ligated rats correlates with increased hepatic IL-17 and TGF-β2 expression. Ann Hepatol. 2016;15(3):418–426.
   PubMed Web of Science ®Google Scholar
• Giles DA, Moreno-Fernandez ME, Divanovic S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets. 2015;16(12):1315–1323.
   PubMed Web of Science ®Google Scholar
• Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777–822.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Conti A, Galdo G, et al. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013;168:1124–1127.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Pastorino R, et al. Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients. Expert Opin Biol Ther. 2018;18(3):229–235.
   PubMed Web of Science ®Google Scholar